HRA Pharma’s former CEO David Wright joins Ceuta Group


Share post:

Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director.

With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim’s consumer business.

During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability.

The company said: “David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company’s successful acquisition by Perrigo Company plc.”

David will take an active role on the Ceuta Group Board supporting and building the company’s strategic vision and priorities. He will also help shape the company’s growth plans on an operational level to ensure Ceuta Group continues to meet client’s needs today and into the future.

Commenting on his new role, David said, “Having worked with Ceuta Group while I was at Boehringer and HRA Pharma, I have first hand experience of how it can deliver maximum impact for clients at all stages of growth development. I’m excited to be joining Ceuta Group at this pivotal time and look forward to being a part of its continued success and growth.”

Edwin Bessant, Ceuta Group CEO, said on behalf of the Board of Directors, “David brings extensive global corporate and industry experience and insight to Ceuta Group.

“He has delivered exceptional commercial outcomes in previous roles and we’re absolutely delighted to have him join Ceuta Group as a non-executive board director. His ability to grow successful businesses and teams across the globe will be significant to the future growth of Ceuta Group.”


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...